Alder Biopharmaceuticals Inc (ALDR) : Foresite Capital Management Iii scooped up 321,613 additional shares in Alder Biopharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 1,600,183 shares of Alder Biopharmaceuticals Inc which is valued at $49,813,697.Alder Biopharmaceuticals Inc makes up approximately 31.84% of Foresite Capital Management Iii’s portfolio.
Other Hedge Funds, Including , Pioneer Investment Management Inc boosted its stake in ALDR in the latest quarter, The investment management firm added 402,270 additional shares and now holds a total of 824,988 shares of Alder Biopharmaceuticals Inc which is valued at $25,681,876. Alder Biopharmaceuticals Inc makes up approx 0.09% of Pioneer Investment Management Inc’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in ALDR in the latest quarter, The investment management firm added 460,322 additional shares and now holds a total of 1,061,912 shares of Alder Biopharmaceuticals Inc which is valued at $33,057,321. Alder Biopharmaceuticals Inc makes up approx 0.01% of Blackrock Institutional Trust Company N.a.’s portfolio. Neuberger Berman Group added ALDR to its portfolio by purchasing 20,000 company shares during the most recent quarter which is valued at $629,000.Great West Life Assurance Co Can boosted its stake in ALDR in the latest quarter, The investment management firm added 2,534 additional shares and now holds a total of 5,234 shares of Alder Biopharmaceuticals Inc which is valued at $164,138.
Alder Biopharmaceuticals Inc opened for trading at $32.45 and hit $33.24 on the upside on Monday, eventually ending the session at $32.88, with a gain of 1.48% or 0.48 points. The heightened volatility saw the trading volume jump to 4,38,472 shares. Company has a market cap of $1,650 M.
On the company’s financial health, Alder Biopharmaceuticals Inc reported $-0.76 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.72.Analysts expectations of $ .14.During the same quarter in the previous year, the company posted $-0.40 EPS.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.